AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12271721
Drug: Adult live
RxNorm normalized name: Heterologous human adult liver derived progenitor cells
DrugBank: Heterologous human adult liver derived progenitor cells (DB17695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult live influenza vaccine (LIVII)
Trial: 12271721
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (LIVI and LIVII)
Trial: 7769082
Drug: Misoprostol (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (after mifepristone pre-treatment)
Trial: 2186323
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acylaminopenicillin plus aminoglycoside
Trial: 2186323
Drug: Double beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double beta lactam therapy
Trial: 31519284
Drug: WEACURE® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEACURE® (500 mg of Jadwar root powder)
Trial: 28424257
Drug: Animal-source food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-source food (ASF) supplement (mean: 144 kcal, 8.9 mg Fe, 2.7 mg Zn, 1050 μg retinoic acid equivalent vitamin A, and 5.5 μg vitamin B-12)
Trial: 28424257
Drug: Control snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control snack (mean: 150 kcal, 2.0 mg Fe, 0.9 mg Zn, 0 μg retinoic acid equivalent vitamin A, and 0 μg vitamin B-12)
Trial: 28424257
Drug: Animal-source food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-source food (ASF) supplement
Trial: 24809429
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplementation (ONS) - 2 servings (460 mL) daily providing 432 kcal, 16 g protein, and 28 micronutrients for 12 weeks
Trial: 24809429
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplementation (ONS)
Trial: 21349111
Drug: comb-NBUVB (NBUVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comb-NBUVB (NBUVB therapy with daily application of antimicrobial gel)
Trial: 21349111
Drug: mono-NBUVB (NBUVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mono-NBUVB (NBUVB therapy without antimicrobial gel)
Trial: 21349111
Drug: NBUVB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBUVB treatment (both comb-NBUVB and mono-NBUVB)
Trial: 12504395
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate (2 mg, daily for 2 years)
Trial: 8558626
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (300 mg per kg of body mass)
Trial: 8558626
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg sodium chloride per kg of body mass and 200 mg calcium carbonate per kg of body mass)
Trial: 637277
Drug: Caudad injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudad injection via a 22 gauge Whitacre needle
Trial: 637277
Drug: Cephalad or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalad or lateral injection via a 22 gauge Whitacre needle
Trial: 637277
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose caudally directed injections
Trial: 29264882
Drug: Removable appliance
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable appliance therapy with electronic sensors for cooperation assessment
Trial: 23501141
Drug: Internal motivations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal motivations for seeking treatment
Trial: 23501141
Drug: General motivations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General motivations for seeking treatment
Trial: 16404515
Drug: High-dose intracoronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intracoronary brachytherapy (24 Gy)
Trial: 31863206
Drug: Pregabalin (PG)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PG) 150 mg per os, 2 doses preoperatively
Trial: 26284299
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (expected to eat less than 300 g of fish and mussels per week)
Trial: 23026173
Drug: 0.125% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% levobupivacaine plus 3 mg fentanyl
Trial: 23026173
Drug: 0.1% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% levobupivacaine plus 3 mg fentanyl
Trial: 23026173
Drug: 0.05% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% levobupivacaine plus 3 mg fentanyl
Trial: 19740915
Drug: CyA (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA (AUC 1700‐2000 ng/ml) + PSL (0.8 mg/kg/day)
Trial: 19740915
Drug: PSL alone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSL alone (1.0 mg/kg/day)
Trial: 18801159
Drug: Standard arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm: total dose 6.0 Gy in single fractions of 1.0 Gy applied twice a week
Trial: 18801159
Drug: Experimental arm:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arm: total dose 0.6 Gy in single fractions of 0.1 Gy applied twice a week (acting as a placebo)
Trial: 16052085
Drug: CD4-based co-trimoxazole
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4-based co-trimoxazole initiation (< 500, < 200, < 50 x 10(6) CD4 cells/l)
Trial: 10509848
Drug: Dorzolamide hydrochloride
RxNorm normalized name: Dorzolamide Hydrochloride
DrugBank: Dorzolamide (DB00869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dorzolamide hydrochloride ophthalmic solution 2% TID
Trial: 8750152
Drug: IFN-alpha monotherapy
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha monotherapy
Trial: 819597
Drug: Idoxuridine (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxuridine (given hourly by day and at 2-hr intervals by night for three days)
Trial: 819597
Drug: Human interferon
RxNorm normalized name: Human interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human interferon (1.1 X 10(7) international units/ml, applied daily)
Trial: 819597
Drug: Human interferon
RxNorm normalized name: Human interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human interferon (given once daily for seven days)
Trial: 22094836
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 μg 1,25‐dihydroxy cholecalciferol per capsule, 2 capsules per day)
Trial: 22299644
Drug: 2000 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 µg BDP solution with 5 g oral charcoal (OralC)
Trial: 22299644
Drug: 2000 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 µg BDP solution without oral charcoal (Oral)
Trial: 22299644
Drug: 10,100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,100 µg inhalations from Qvar(®) pMDI (Qvar)
Trial: 22299644
Drug: eight 250
RxNorm normalized name: Novoeight 250units Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eight 250 µg inhalations from Clenil(®) pMDI (Clenil)
Trial: 14630756
Drug: Steroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid and acetic acid ear drops
Trial: 14630756
Drug: Steroid and
RxNorm normalized name: Corticosteroid and/or corticosteroid derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid and antibiotic ear drops
Trial: 9797832
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) (10 mg/kg)
Trial: 7653663
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion (0.4 micrograms.kg‐1.min‐1)
Trial: 799974
Drug: Metoprolol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (150 and 300 mg/day)
Trial: 799974
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 and 240 mg/day)
Trial: 799974
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 and 6 tablets per day)
Trial: 28887592
Drug: Antidepressant DTCA
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant DTCA with portrayals of discrimination, cognitive separation, and stereotyping (DCSS)
Trial: 27179825
Drug: EECP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EECP treatment (35 1‐h sessions)
Trial: 25409886
Drug: Intensive psychological
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive psychological therapy alone
Trial: 20711429
Drug: ZK 200775
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 200775 at 0.03 mg/kg/h
Trial: 20711429
Drug: ZK 200775
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 200775 at 0.75 mg/kg/h
Trial: 20711429
Drug: ZK 200775
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 200775 (both doses)
Trial: 2496240
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy program for urinary incontinence (13 weeks)
Trial: 610325
Drug: Combination induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination induction therapy with vincristine and prednisolone
Trial: 610325
Drug: Cyclic therapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic therapy (721-A) with intermittent high-dose infusion of methotrexate
Trial: 610325
Drug: Cyclic intrathecal
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic intrathecal medication during remission or combination therapy with 2,400 rads cranial irradiation plus intrathecal medication
Trial: 610325
Drug: Patients maintained
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients maintained without further chemotherapy after complete remission
Trial: 610325
Drug: Patients taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients taken off therapy
Trial: 31781755
Drug: Filgotinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib, a selective JAK1 inhibitor
Trial: 31781755
Drug: Tofacitinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib, a pan‐JAK inhibitor
Trial: 25952317
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg twice daily followed by sunitinib 50mg once daily (4 wk on, 2 wk off)
Trial: 25952317
Drug: Sunitinib 50mg
RxNorm normalized name: sunitinib 50 MG
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 50mg once daily (4 wk on, 2 wk off) followed by sorafenib 400mg twice daily
Trial: 22092152
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (pelvic floor muscle exercises, urge suppression techniques, delayed voiding)
Trial: 22092152
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (individually titrated, extended‐release oxybutynin, 5‐30 mg/d)
Trial: 19673667
Drug: torasemide-PR (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: torasemide-PR (10-40 mg daily)
Trial: 19673667
Drug: furosemide (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furosemide (40-160 mg daily)
Trial: 10966703
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (in patients aged 2 years or younger with grade IV VUR, bilateral VUR, or renal scars)
Trial: 10966703
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (in patients with unilateral renal scarring or thin parenchyma)
Trial: 10966703
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (in patients with bilateral renal scarring)
Trial: 8990731
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (three 15-minute massages daily for 10 days)
Trial: 1731418
Drug: Nimodipine 120
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 120 mg daily
Trial: 31363811
Drug: Subfascial implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subfascial implant placement
Trial: 31363811
Drug: Subglandular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subglandular implant placement
Trial: 29465751
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus surgery (CS) group
Trial: 25231089
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: lansoprazole 30 mg bid, amoxicillin 1.0 g tid, rifabutin 150 mg bid for 7 days
Trial: 25231089
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: lansoprazole 60 mg bid, amoxicillin 1.0 g tid, rifabutin 150 mg bid for 7 days
Trial: 22313068
Drug: Control (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (blood cardioplegia without L-arginine)
Trial: 19837545
Drug: Moderate lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate lipid-lowering therapy with low-dose atorvastatin (10 mg-20 mg)
Trial: 19837545
Drug: Aggressive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lipid-lowering therapy with high-dose atorvastatin (80 mg)
Trial: 16533867
Drug: Guaraná extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaraná extract 37.5 mg
Trial: 16533867
Drug: Guaraná extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaraná extract 75 mg
Trial: 16533867
Drug: Guaraná extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaraná extract 150 mg
Trial: 16533867
Drug: Guaraná extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guaraná extract 300 mg
Trial: 16239201
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at a dose equal to the mean of their total daily CSII basal insulin dose (group 1:1)
Trial: 16239201
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at a dose of 1.2 times the mean of their total daily CSII basal insulin dose (group 1:1.2)
Trial: 12204788
Drug: 4% Dextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Dextrin sulphate (DS) gel applied topically to the penis once per day for 14 consecutive days, left on for a minimum of 6 hours.
Trial: 12204788
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied topically to the penis once per day for 14 consecutive days, left on for a minimum of 6 hours.
Trial: 10567865
Drug: 0.1% indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% indomethacin solution
Trial: 1924667
Drug: Haloperidol (neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (neuroleptic threshold doses)
Trial: 6356924
Drug: Cefoxitin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (3 doses of 2 gm intramuscularly over 12 hours)
Trial: 26188849
Drug: Ethanol locks
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol locks (1.5 or 3 ml 70%)
Trial: 26188849
Drug: Heparin locks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin locks (1.5 or 3 ml 100 IU/ml)
Trial: 24095901
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for Panic Disorder, 11 sessions
Trial: 16680475
Drug: Saline-adrenaline-lidocaine solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline-adrenaline-lidocaine solution injected (40 ml)
Trial: 11063905
Drug: Kliogest (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kliogest (norethisterone acetate 1 mg and oestradiol valerate 2 mg)
Trial: 2856601
Drug: Amikacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (500 mg every 12 hours) and Ticarcillin (3 gm every six or eight hours)
Trial: 25754510
Drug: Proaftol spray,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proaftol spray, applied as two sprayings on the site of the aphthae 3-4 times a day.
Trial: 25754510
Drug: Placebo spray,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray, applied as two sprayings on the site of the aphthae 3-4 times a day.
Trial: 25754510
Drug: Proaftol spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proaftol spray
Trial: 10945311
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg administered simultaneously with ketoconazole 200 mg
Trial: 10945311
Drug: Budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 3 mg administered 12 hours before ketoconazole 200 mg
Trial: 10945311
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg administered once daily in the morning
Trial: 9493660
Drug: Control: ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: ambient temperature (tamb) = 25 degrees C, rectal temperature change (delta tre) = 0 degrees C
Trial: 8399251
Drug: Previous dental
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous dental visits and procedures, oral hygiene instruction, and x‐rays
Trial: 3091801
Drug: Cefadroxil 30
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefadroxil 30 mg/kg once daily for 10 days
Trial: 3091801
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 250 mg three times daily for 10 days
Trial: 3091801
Drug: Cefadroxil 30
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefadroxil 30 mg/kg once daily
Trial: 3091801
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 250 mg three times daily
Trial: 31307747
Drug: Alfentanil (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (15 μg/kg)
Trial: 31307747
Drug: Fentanyl (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.5 μg/kg)
Trial: 31307747
Drug: Remifentanil (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1.5 μg/kg)
Trial: 29058822
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg every 4 weeks for 28 weeks
Trial: 22203120
Drug: IT injection
RxNorm normalized name: chymopapain 4 unit INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT injection without any previous anesthesia
Trial: 22203120
Drug: IT injection
RxNorm normalized name: chymopapain 4 unit INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT injection with EMLA cream
Trial: 22203120
Drug: IT injection
RxNorm normalized name: chymopapain 4 unit INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT injection with subcutaneous lidocaine 1%
Trial: 22203120
Drug: IT injection
RxNorm normalized name: chymopapain 4 unit INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT injection with methylprednisolone
Trial: 22203120
Drug: IT injection
RxNorm normalized name: chymopapain 4 unit INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT injection with gentamicin
Trial: 21029874
Drug: Augmentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation of ST-segment elevation ≥0.05 mV in V(1) to V(3) leads during early recovery (1 to 4 min)
Trial: 21029874
Drug: No augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmentation of ST-segment elevation
Trial: 12173947
Drug: Low-dose creatine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose creatine supplementation